beta-amyloid burden is not associated with rates of brain atrophy.

beta-amyloid burden is not associated with rates of brain atrophy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

beta-amyloid burden is not associated with rates of brain atrophy. Abstract Text:

Keith A Josephs,Jennifer L Whitwell,Zeshan Ahmed,Maria M Shiung,Stephen D Weigand,David S Knopman,Bradley F Boeve,Joseph E Parisi,Ronald C Petersen,Dennis W Dickson,Clifford R Jack,

OBJECTIVE: To test the hypothesis that beta-amyloid (Abeta) burden is associated with rates of brain atrophy. METHODS: Forty-five subjects who had been prospectively studied, died, and had an autopsy diagnosis of low, intermediate, or high probability of Alzheimer's disease who had two volumetric head magnetic resonance imaging scans were identified. Compact and total (compact + diffuse) Abeta burden was measured using a computerized image analyzer with software program to detect the proportion of gray matter occupied by Abeta. Visual ratings of Abeta burden were also performed. The boundary shift integral was used to calculate change over time in whole-brain and ventricular volume. All boundary shift integral results were annualized by adjusting for scan interval. Demographics, cognitive measures, clinical diagnoses, apolipoprotein E genotype, neurofibrillary tangle (NFT) pathology, and vascular lesion burden were determined. RESULTS: There was no correlation between compact or total Abeta burden, or visual Abeta ratings, and rates of brain loss or ventricular expansion in all subjects. However, significant correlations were observed between rates of brain loss and age, Braak NFT stage, and change over time in cognitive measures. These features also correlated with rates of ventricular expansion. The rates of brain loss and ventricular expansion were greater in demented compared with nondemented subjects. INTERPRETATION: These findings suggest that rate of brain volume loss is not determined by the amount of insoluble Abeta in the gray matter. Ann Neurol 2007.

beta-amyloid burden is not associated with rates of brain atrophy. Publishing Authors By Initials

KA Josephs,JL Whitwell,Z Ahmed,MM Shiung,SD Weigand,DS Knopman,BF Boeve,JE Parisi,RC Petersen,DW Dickson,CR Jack,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

beta-amyloid burden is not associated with rates of brain atrophy. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Annals of neurology

VOLUME: 63

Page Numbers: 204-12

Journal Abbreviation: Ann. Neurol.

ISSN: 1531-8249

DAY: 4

MONTH: Feb

YEAR: 2008

beta-amyloid burden is not associated with rates of brain atrophy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7707449

beta-amyloid burden is not associated with rates of brain atrophy. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: beta-amyloid burden is not associated with rates of brain atrophy. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for beta-amyloid burden is not associated with rates of brain atrophy.

AFFILIATION: Department of Neurology, Mayo Clinic, Rochester, MN.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ann Neurol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

beta-amyloid burden is not associated with rates of brain atrophy Related Publications

• 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease.
• A critical analysis of local anesthesia as an agent for the relief of pain in vaginal delivery.
• Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies.
• Applying comprehensive community-based approaches in diabetes prevention: rationale, principles, and models.
• Assessment of functional MR imaging in neurosurgical planning.
• Balancing Big Pharma's books.
• Bone anomalies of the tarsus in relation to peroneal spastic flat foot.
• Conserved C-terminal motifs of the Arabidopsis proteins APETALA3 and PISTILLATA are dispensable for floral organ identity function.
• Counterfeit medicines. Bitter pills.
• DORNROSCHEN-LIKE, an AP2 gene, is necessary for stamen emergence in Arabidopsis.
• EWEN ALISTAIR JACK, 1909-1953.
• Experimental rupture of the medial collateral ligament of the knee.
• Functional heterogeneity of the supplementary motor area.
• Hippocampal T2 relaxometry in epilepsy: past, present, and future.
• Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease.
• MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment.
• Medial temporal lobe volumetrics in traumatic brain injury.
• Naviculo-cuneiform fusion in the treatment of flat foot.
• Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience.
• Patterns of atrophy differ among specific subtypes of mild cognitive impairment.
• Plasma ascorbic acid levels in Nigerian children of Niger delta region of Nigeria.
• Posterior peripheral detachment of the lateral cartilage.
• Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T.
• Relation of triglycerides to phosphoglycerides in fungi.
• Structure and dynamics of glass formers: Predictability at large length scales.
• Understanding rehospitalization risk: can hospital discharge be modified to reduce recurrent hospitalization?
• Use of milk fat fractions in baked products.
• Voxel-based morphometry in autopsy proven PSP and CBD.
• [A nurse sees her professional colleagues at the bedside of her sick mother. Nurses: competent and insensitive]
• ef1097 and ypkK encode enterococcin V583 and corynicin JK, members of a new family of antimicrobial proteins (bacteriocins) with modular structure from Gram-positive bacteria.